Other languages Lytix Biopharma

Equities

LYTIX

NO0010405780

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-10 EDT			5-day change	1st Jan Change
5.48 ^NOK	+0.37%		-6.48%	+12.76%

04-25	Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	CI
04-10	Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	04-25
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	04-10
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	01-05
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology	12-11
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Lytix Biopharma AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31
Lytix Biopharma Completes Patient Enrollment for LTX-315 Trial	23-08-28
Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial	23-08-28
Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315	23-08-11
Lytix Biopharma AS Announces Presentation of Interim Data from ATLAS-IT-05 Study at ESMO 2023	23-07-19
Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Lytix Biopharma Elects New Chair	23-04-19
Lytix Biopharma AS Appoints Marie Ann Roskrow as New Chairman of the Board	23-04-18
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17
Lytix Biopharma AS Announces Expansion of the ATLAS-IT-05 Study to Europe	22-11-14
Lytix Biopharma Announces Site Activation for the ATLAS-IT-05 Study in Three European Countries	22-11-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lytix Biopharma

Equities

LYTIX

NO0010405780

Other languages

Filters